We are live on ! Find out more
ALGS icon

Aligos Therapeutics
ALGS

33 hedge funds and large institutions have $26M invested in Aligos Therapeutics in 2025 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 11 increasing their positions, 6 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

83% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 6

33% more capital invested

Capital invested by funds: $19.5M → $26M (+$6.48M)

1.37% less ownership

Funds ownership: 50.92% → 49.55% (-1.4%)

11% less funds holding

Funds holding: 37 → 33 (-4)

44% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 9

Holders
33
Holders Change
-4
Holders Change %
-10.81%
% of All Funds
0.43%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
11
Reduced
6
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RAM
Readystate Asset Management
Illinois
+$606K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$292K
3
Two Sigma Investments
Two Sigma Investments
New York
+$246K
4
LPL Financial
LPL Financial
California
+$229K
5
UBS Group
UBS Group
Switzerland
+$123K

Top Sellers

Rank Fund Capital Flow
1
TCM
Tang Capital Management
California
-$1.02M
2
WP
Woodline Partners
California
-$458K
3
Charles Schwab
Charles Schwab
California
-$183K
4
XT
XTX Topco
Cayman Islands
-$99.9K
5
Wells Fargo
Wells Fargo
California
-$96.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
Rockefeller Capital Management
26
Rockefeller Capital Management
New York
$9.8K +$9.14K +1,000 New
GRP
27
Global Retirement Partners
California
$7.84K +$7.31K +800 New
JP Morgan Chase
28
JP Morgan Chase
New York
$6.94K +$6.23K +682 +2,623%
TRCT
29
Tower Research Capital (TRC)
New York
$4.48K -$5.9K -646 -59%
SS
30
SBI Securities
Japan
$255 – – –
Barclays
31
Barclays
United Kingdom
$147 +$137 +15 New
EWP
32
Elevation Wealth Partners
California
$40 – – –
BNP Paribas Financial Markets
33
BNP Paribas Financial Markets
France
$29 -$16.6K -1,813 -100%
TCM
34
Tang Capital Management
California
– -$1.02M -141,131 Closed
Charles Schwab
35
Charles Schwab
California
– -$183K -25,398 Closed
XT
36
XTX Topco
Cayman Islands
– -$99.9K -13,849 Closed
Millennium Management
37
Millennium Management
New York
– -$88.8K -12,315 Closed
Goldman Sachs
38
Goldman Sachs
New York
– -$73.8K -10,231 Closed
Acadian Asset Management
39
Acadian Asset Management
Massachusetts
– -$28K -3,913 Closed
Raymond James Financial
40
Raymond James Financial
Florida
– -$3.6K -500 Closed
Osaic Holdings
41
Osaic Holdings
Arizona
– -$1.59K -220 Closed
Fidelity Investments
42
Fidelity Investments
Massachusetts
– -$72 -10 Closed
1
2

ALGS Hedge Fund Activity: Q3 2025 in Review

33 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Aligos Therapeutics (ALGS) for Q3 2025, worth a combined $26M — up 33% from $19.5M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of ALGS and 5 opened new positions — a net loss of 4 holders — while 6 trimmed existing stakes and 11 added.

The largest buyer was Readystate Asset Management, adding an estimated $606K. The largest seller was Tang Capital Management, exiting entirely with an estimated $1.02M sold.

  • 33 institutional investors held Aligos Therapeutics (ALGS) as of Q3 2025, down from 37 in Q2 2025.
  • Funds reported $26M of Aligos Therapeutics stock for Q3 2025, up 33% quarter-over-quarter.
  • 5 funds opened new Aligos Therapeutics positions in Q3 2025 and 9 closed out, a net change of -4 holders.
  • The largest Aligos Therapeutics buyer in Q3 2025 was Readystate Asset Management, an estimated $606K added.
  • The largest Aligos Therapeutics seller in Q3 2025 was Tang Capital Management, an estimated $1.02M sold.

Based on aggregated 13F filings for Q3 2025.